Vor Biopharma (VOR)Ra Capital Management, L.P. reduced its stake -3M shares

2.4M

Shares reported · -3M vs prior quarter

0.38%

Disclosed portfolio weight

$44.2M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Vor Biopharma

For Vor Biopharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VOR page.

How this filing works

• SEC Form 13F

Other disclosures at Vor Biopharma

• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Sep 19, 2025
• SEC Form 4Sep 15, 2025

Everything OQRO holds on this company is on its VOR page.